Special collections

Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses
Yijun Dong, Zongliang Zhang, Siyuan Luan, Meijun Zheng, Zeng Wang, Yongdong Chen, Xiaoting Chen, Aiping Tong, Hui Yang

Journal for ImmunoTherapy of Cancer Oct 2024, 12 (10) e009710; DOI: 10.1136/jitc-2024-009710
Gal-3 blocks the binding between PD-1 and pembrolizumab
Stinne Ravn Greisen, Mia Bendix, Morten Aagaard Nielsen, Kathrine Pedersen, Nina Haunstrup Jensen, Malene Hvid, Jakob Hauge Mikkelsen, Taner Drace, Thomas Boesen, Torben Steiniche, Henrik Schmidt, Bent Deleuran

Journal for ImmunoTherapy of Cancer Oct 2024, 12 (10) e009952; DOI: 10.1136/jitc-2024-009952
Cancer cell-specific PD-L1 expression is a predictor of poor outcome in patients with locally advanced oral cavity squamous cell carcinoma
Minyu Wang, Lei Qin, Kevin Thia, Thu Nguyen, Sean MacDonald, Simone Belobrov, Sevastjan Kranz, David Goode, Joseph A Trapani, David Wiesenfeld, Paul Joseph Neeson

Journal for ImmunoTherapy of Cancer Oct 2024, 12 (10) e009617; DOI: 10.1136/jitc-2024-009617
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
Idris Bahce, Chris Dickhoff, Famke L Schneiders, Joris Veltman, David J Heineman, Sayed M S Hashemi, Anne Vrijmoet, Ilias Houda, Ezgi B Ulas, Joyce Bakker, Peter van de Ven, Natalja Bouwhuis, Lilian J Meijboom, Daniela E Oprea-Lager, Febe van Maldegem, Marieke F Fransen, Tanja D de Gruijl, Teodora Radonic, Suresh Senan

Journal for ImmunoTherapy of Cancer Sep 2024, 12 (9) e009799; DOI: 10.1136/jitc-2024-009799
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses
Nathan D Seligson, James L Chen, Austin C Goodrich, Brian A Van Tine, Jordan D Campbell, Allison L Richards, Cristina R Antonescu, David A Liebner, Mohammed M Milhem, Howard Streicher, William D Tap, Gary K Schwartz, Suzanne George, Sandra P D'Angelo

Journal for ImmunoTherapy of Cancer Sep 2024, 12 (9) e009472; DOI: 10.1136/jitc-2024-009472
Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade
Nicola Principe, Amber-Lee Phung, Kofi L P Stevens, Omar Elaskalani, Ben Wylie, Caitlin M Tilsed, Fezaan Sheikh, M Lizeth Orozco Morales, Joel Kidman, Elly Marcq, Scott A Fisher, Anna K Nowak, Alison M McDonnell, W Joost Lesterhuis, Jonathan Chee

Journal for ImmunoTherapy of Cancer Sep 2024, 12 (9) e008568; DOI: 10.1136/jitc-2023-008568
Inhibition of the NF-κB/HIF-1α signaling pathway in colorectal cancer by tyrosol: a gut microbiota-derived metabolite
Jian Guo, Fanqi Meng, Ruixue Hu, Lei Chen, Jiang Chang, Ke Zhao, Honglin Ren, Zengshan Liu, Pan Hu, Guangyi Wang, Jiandong Tai

Journal for ImmunoTherapy of Cancer Sep 2024, 12 (9) e008831; DOI: 10.1136/jitc-2024-008831
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors
Young Kwang Chae, Megan Othus, Sandip Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan, Silvana Bucur, Hye Sung Kim, Liam IL-Young Chung, Christine McLeod, Helen X Chen, Elad Sharon, Howard Streicher, Christopher W Ryan, Charles Blanke, Razelle Kurzrock

Journal for ImmunoTherapy of Cancer Sep 2024, 12 (9) e009128; DOI: 10.1136/jitc-2024-009128
Targeting epigenetic regulation and post-translational modification with 5-Aza-2’ deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy
Jessie S Kroonen, Anne K Wouters, Ilona J de Graaf, Dennis F G Remst, Sumit Kumar, Tassilo L A Wachsmann, Amina F A S Teunisse, Jessica P Roelands, Noel F C C de Miranda, Marieke Griffioen, Mirjam H M Heemskerk, Alfred C O Vertegaal

Journal for ImmunoTherapy of Cancer Sep 2024, 12 (9) e008654; DOI: 10.1136/jitc-2023-008654
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
Xuewei Wu, Jingjing You, Shuixing Zhang, Bin Zhang

Journal for ImmunoTherapy of Cancer Sep 2024, 12 (9) e010330; DOI: 10.1136/jitc-2024-010330

Main menu

Special collections

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Special collections

Pages